Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab first-in-human safety trial in malignant solid tumors
2023-509059-15-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of acasunlimab in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), endometrial cancer (EC) and 4 more (3 arms), sponsored by Genmab. Primary endpoints: Number of participants with dose-limiting toxicity, Number of participants with adverse events and 2 more. Started Jul 2024; status: completed.
02
Drugs
acasunlimab
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)endometrial cancer (EC)transitional cell carcinoma (TCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-509059-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509059-15-00.